We are live on ! Find out more
ERNAW

Ernexa Therapeutics Warrants
ERNAW

5 hedge funds and large institutions have $195K invested in Ernexa Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

50.02% more ownership

Funds ownership: 0% → 50.02% (+50%)

Holders
5
Holders Change
+5
Holders Change %
–
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$237K
2
BL
Bleichroeder LP
New York
+$118K
3
HCM
Heights Capital Management
California
+$23.7K
4
WAM
Warberg Asset Management
Illinois
+$15K
5
CS
Clear Street
New York
+$8.84K

Top Sellers

No sellers this quarter

ERNAW Hedge Fund Activity: Q1 2026 in Review

5 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics Warrants (ERNAW) for Q1 2026, worth a combined $195K.

Buyers outnumbered sellers: 5 funds opened new ERNAW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $237K.

  • 5 institutional investors held Ernexa Therapeutics Warrants (ERNAW) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $195K of Ernexa Therapeutics Warrants stock for Q1 2026.
  • 5 funds opened new Ernexa Therapeutics Warrants positions in Q1 2026 and 0 closed out, a net change of +5 holders.
  • The largest Ernexa Therapeutics Warrants buyer in Q1 2026 was Armistice Capital, an estimated $237K added.

Based on aggregated 13F filings for Q1 2026.